Eye Transplant (Ocular Tissue) in India
Get Eye Transplant (Ocular Tissue) at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Eye Transplant (Ocular Tissue) in UAE
Eye Transplant (Ocular Tissue) at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Eye transplant and ocular tissue transplantation — encompassing corneal transplantation (keratoplasty), scleral grafting, amniotic membrane transplantation, and limbal stem cell transplantation — are advanced ophthalmic procedures that restore vision and ocular surface integrity in patients with corneal blindness, limbal stem cell deficiency, and severe ocular surface disease. Modern techniques such as DSAEK (Descemet's Stripping Automated Endothelial Keratoplasty) and DMEK (Descemet's Membrane Endothelial Keratoplasty) achieve graft survival rates exceeding 90% at five years in high-volume centers. GAF Healthcare connects international patients with JCI- and NABH-accredited hospitals in India and JCI- and DHA-licensed eye centers in Dubai and Abu Dhabi, offering world-class surgical outcomes at a fraction of Western costs, with end-to-end coordination from visa facilitation to post-operative monitoring.
Hospital Stay: 1–3 days (day surgery for lamellar techniques; 1–3 days inpatient for penetrating keratoplasty or complex ocular surface reconstruction) • Total Stay in Country (Fit-to-Fly): 3–6 weeks (minimum 3 weeks post-operatively before safe international air travel; 6 weeks preferred for penetrating keratoplasty or multi-tissue procedures) • Success Rate: 90–95% graft survival at 5 years for DMEK/DSAEK; 80–85% for full-thickness penetrating keratoplasty in standard-risk eyes
What Is It?
Corneal blindness affects an estimated 4.9 million people globally and represents the fourth leading cause of blindness worldwide. The cornea — the transparent, dome-shaped anterior surface of the eye — is responsible for approximately 65–75% of the eye's total refractive power. When the corneal stroma, endothelium, or epithelial stem cell reservoir is irreversibly damaged by conditions such as Fuchs' endothelial dystrophy, keratoconus, bullous keratopathy, herpetic stromal scarring, chemical or thermal burns, or failed prior grafts, vision becomes severely impaired or lost entirely. Unlike vascularized organ transplants, the cornea is an immune-privileged tissue sustained by aqueous humor rather than direct blood supply, which substantially reduces — though does not eliminate — rejection risk and negates the need for systemic immunosuppression in most lamellar cases.
Ocular tissue transplantation has undergone a paradigm shift over the past two decades, moving away from full-thickness penetrating keratoplasty (PK) toward selective anatomical layer replacement. Endothelial keratoplasty techniques — specifically DSAEK and the more refined DMEK — replace only the diseased posterior corneal endothelium, preserving the patient's own stroma and Bowman's layer. This approach yields faster visual rehabilitation (weeks versus months), a stronger wound architecture, reduced astigmatism, and lower rejection rates (approximately 1% per year for DMEK versus 5–8% for PK). For anterior stromal disease such as keratoconus or anterior dystrophies, Deep Anterior Lamellar Keratoplasty (DALK) replaces the stroma while leaving the host endothelium intact, conferring a virtually zero risk of endothelial rejection. Limbal stem cell transplantation (LSCT) — using autologous, allogeneic, or ex vivo–expanded conjunctival limbal grafts — addresses stem cell deficiency conditions where conventional keratoplasty would inevitably fail due to ongoing epithelial breakdown.
The standard of care at GAF Healthcare's partner institutions integrates preoperative topographic and tomographic mapping (Scheimpflug imaging via Pentacam, anterior-segment OCT), endothelial cell density counting by specular or confocal microscopy, HLA tissue typing for high-risk recipients, and intraoperative use of femtosecond laser platforms (VisuMax, FEMTO LDV) for precision donor trephination in DALK and PK procedures. Postoperatively, patients are managed with topical corticosteroid tapers (typically prednisolone acetate 1% or fluorometholone), prophylactic topical antivirals in herpetic disease, and cyclosporine 0.05% or 0.1% ophthalmic emulsion for ocular surface modulation. High-risk recipients may additionally receive low-dose systemic mycophenolate mofetil or tacrolimus to protect vascularized or repeat grafts.
Candidates
• ELIGIBLE CONDITIONS:
• Fuchs' endothelial corneal dystrophy (stages III–IV with endothelial cell density below 500 cells/mm²)
• Bullous keratopathy secondary to cataract surgery, glaucoma surgery, or Fuchs' dystrophy
• Advanced keratoconus or pellucid marginal degeneration with contact lens intolerance or hydrops
• Corneal stromal scarring from infectious keratitis (bacterial, fungal, herpetic, acanthamoeba)
• Chemical or thermal burn–related ocular surface disease with limbal stem cell deficiency (LSCD)
• Macular corneal dystrophy, lattice dystrophy, or granular dystrophy causing visually significant scarring
• Congenital hereditary endothelial dystrophy (CHED) in pediatric patients
• Aniridia-associated keratopathy with confirmed LSCD
• Failed prior corneal graft (repeat keratoplasty)
• Traumatic corneal perforation or descemetocele requiring tectonic reconstruction
• REQUIRED PREOPERATIVE DIAGNOSTICS:
• Slit-lamp biomicroscopy with photographic documentation
• Specular or confocal microscopy (endothelial cell density, morphology, coefficient of variation)
• Scheimpflug tomography / Pentacam HR (corneal topography, pachymetry, anterior-segment parameters)
• Anterior-segment OCT (AS-OCT) for lamellar plane assessment in DALK candidates
• B-scan ocular ultrasonography (posterior segment evaluation when media opacity precludes fundoscopy)
• Intraocular pressure measurement (Goldmann applanation or non-contact tonometry)
• HLA-A, HLA-B, HLA-DR typing for high-risk or repeat-graft recipients
• Systemic workup: CBC, metabolic panel, coagulation screen, blood group, HIV/HBsAg/HCV serology, chest X-ray
• Blood glucose and HbA1c in diabetic patients
• Urine pregnancy test in women of childbearing age
• CONTRAINDICATIONS (ABSOLUTE):
• Active ocular infection (bacterial, fungal, viral) — must be fully treated and quiescent before surgery
• Uncontrolled glaucoma with advanced optic neuropathy (poor visual potential even with clear graft)
• Severe dry eye disease or exposure keratopathy not amenable to correction (predict graft failure)
• Significant retinal disease limiting visual potential (macular degeneration, optic atrophy, retinal detachment)
• Uncontrolled systemic autoimmune disease or active immunosuppression–related infection
• RELATIVE CONTRAINDICATIONS / RISK FACTORS:
• Corneal neovascularization involving more than two quadrants (increases rejection risk 4–8 fold)
• Prior failed grafts (×2 or more) without HLA matching strategy
• Uncontrolled diabetes (HbA1c >9%) — impairs healing and infection resistance
• Active ocular surface inflammation (rosacea keratitis, atopic keratoconjunctivitis) — must be medically optimized first
• Pediatric recipients under 3 years (amblyopia management critical; general anesthesia required)
Procedure
FULL-THICKNESS PENETRATING KERATOPLASTY (PK / PKP):
The historically standard procedure, PK involves complete excision of the host cornea (typically 7.5–8.5 mm trephine) and suturing of a full-thickness donor button using 16 interrupted 10-0 nylon sutures or a running suture technique. Visual recovery is slow (12–24 months), surgically induced astigmatism is significant (3–5 D), and the wound remains a structural weak point lifelong. PK remains the procedure of choice for full-thickness scarring, perforation, or conditions requiring tectonic reconstruction. Femtosecond laser–assisted PK (using the FEMTO LDV or IntraLase platform) allows creation of complex wound geometries (zig-zag, mushroom, top-hat profiles) that enhance wound strength and reduce astigmatism.
DEEP ANTERIOR LAMELLAR KERATOPLASTY (DALK):
DALK replaces the anterior stroma while preserving the patient's own Descemet's membrane and endothelium. The 'big-bubble' technique (Anwar technique) — injecting intrastromal air at 30 psi to pneumatically dissect a cleavage plane at the pre-Descemet's (Dua's) layer — achieves a reliable optical interface in experienced hands. Advantages include virtual elimination of endothelial rejection risk, retention of host endothelium, and easier management of intraoperative perforations by converting to PK. DALK is preferred for keratoconus, anterior stromal dystrophies, and herpetic stromal scarring with intact endothelium. Visual outcomes are comparable to PK; refractive predictability is improving with wavefront-guided donor selection.
DSAEK (DESCEMET'S STRIPPING AUTOMATED ENDOTHELIAL KERATOPLASTY):
DSAEK selectively replaces the diseased endothelium along with a 100–200 µm posterior stromal carrier. A small (4–5 mm) scleral or corneal incision is used, the host endothelium is stripped (descemetorhexis), and a pre-cut donor lenticule is inserted folded and unfolded using a glide or injector system (Busin glide, EndoGlide, DSAEK inserter). An air or SF6 gas bubble is injected to tamponade the graft against the stroma. Visual recovery is 3–6 months; best-corrected visual acuity typically reaches 20/25–20/40. DSAEK remains widely available, with a robust global supply chain for pre-cut tissue from accredited eye banks.
DMEK (DESCEMET'S MEMBRANE ENDOTHELIAL KERATOPLASTY):
DMEK represents the current gold standard for Fuchs' dystrophy and bullous keratopathy. Only the Descemet's membrane (8–12 µm) with its adherent endothelial monolayer is transplanted — no stromal carrier. A rolled donor scroll is injected through a 2.8–3.2 mm incision and unscrolled in the anterior chamber using targeted fluid dynamics and air injection. Rejection rates are approximately 1% per year (versus 5–8% for PK), and visual outcomes are superior — over 70% of patients achieve 20/20 or better by 6 months. DMEK requires specialized surgical training and appropriate eye bank preparation (pre-scored or pre-stripped tissue). Ultra-thin DSAEK (UT-DSAEK, <100 µm) offers a technical bridge between DSAEK and DMEK for surgeons in transition.
LIMBAL STEM CELL TRANSPLANTATION (LSCT):
For eyes with LSCD (ocular burns, aniridia, Stevens-Johnson syndrome, chronic limbitis), keratoplasty alone fails because the epithelial regeneration capacity is lost. LSCT options include: (1) Conjunctival Limbal Autograft (CLAU) — harvesting limbal tissue from the fellow unaffected eye; (2) Living-related conjunctival limbal allograft (lr-CLAL) — from a first-degree relative, requiring HLA matching and systemic immunosuppression; (3) Cultivated Limbal Epithelial Transplantation (CLET) — ex vivo expansion of autologous or allogeneic limbal cells on an amniotic membrane or fibrin scaffold in a GMP-certified laboratory, then transplantation; (4) Simple Limbal Epithelial Transplantation (SLET) — a low-cost, single-stage technique wherein a small limbal biopsy is directly transplanted onto an amniotic membrane placed on the host cornea. CLET and SLET have demonstrated 70–80% success in re-epithelializing previously failed corneas over 12–24 months, followed by keratoplasty for residual stromal opacity.
AMNIOTIC MEMBRANE TRANSPLANTATION (AMT):
AMT uses preserved human amniotic membrane (cryopreserved or lyophilized) as a biological scaffold with anti-inflammatory, anti-fibrotic, and pro-epitheliogenic properties. It is indicated for persistent epithelial defects, chemical burns (acute and chronic), symblepharon release, pterygium surgery, and as a carrier for CLET/SLET. Sutureless techniques (ProKera ring-mounted membrane) allow office-based application. AMT is frequently used as a preparatory procedure before definitive keratoplasty.
SCLERAL PATCH GRAFTING:
Used for tectonic reinforcement in eyes with corneal or scleral thinning, perforation, or following glaucoma drainage device placement. Donor scleral tissue is trimmed and sutured over the defect with 8-0 or 9-0 nylon. Glycerin-preserved scleral allografts from certified eye banks are the standard source.
ADVANCED TECHNOLOGIES AT PARTNER CENTERS:
• Femtosecond laser platforms (VisuMax Carl Zeiss, FEMTO LDV Ziemer) for precision trephination
• Pre-cut and pre-loaded DMEK/DSAEK tissue from ISO/AATB-accredited eye banks
• Intraoperative OCT (iOCT) for real-time graft unfolding guidance during DMEK
• CLET using GMP-certified cell culture laboratories (available at select India centers: L.V. Prasad Eye Institute, Narayana Nethralaya)
• Digital adaptive optics imaging for post-graft endothelial cell density tracking
Cost of Eye Transplant (Ocular Tissue): India vs. UAE
The cost of eye transplant and ocular tissue transplantation varies significantly depending on the surgical technique chosen, the complexity of the recipient eye, the type of donor tissue required, and the destination country. India offers world-class corneal surgery at the lowest price point globally, with specialist volumes at centers like L.V. Prasad Eye Institute, Narayana Nethralaya, and Sankara Nethralaya that rival or exceed those of leading Western academic centers. The UAE — particularly Dubai and Abu Dhabi — provides premium-tier ophthalmic care in state-of-the-art private hospitals such as Moorfields Eye Hospital Dubai, Cleveland Clinic Abu Dhabi, and Al Zahrawi Hospital, at a cost approximately 50–70% higher than India but substantially below comparable procedures in the UK, USA, or Australia. The costs below are all-inclusive estimates in USD and cover surgical fees, anesthesia, donor tissue acquisition and processing, hospitalization, operating room charges, and standard post-operative medications for the in-country stay.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $1,500 – $6,000 | ~58% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $4,000 – $14,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-OPERATIVE EVALUATION (Days 1–5 after arrival):
On Day 1, the patient undergoes a comprehensive ophthalmic evaluation at the partner hospital: slit-lamp examination, specular microscopy, Pentacam tomography, AS-OCT, B-scan ultrasound, intraocular pressure measurement, and full-dilated fundus assessment. Blood investigations (CBC, coagulation, metabolic panel, serology) are drawn. The cornea specialist reviews imaging and establishes the surgical plan (DMEK, DALK, PK, or LSCT). HLA typing results (if ordered) are reviewed. An anesthesia consult is conducted. Eye bank tissue is confirmed — donor endothelial cell density must exceed 2,000 cells/mm² per EBAA/SightLife standards. If topical anti-inflammatory optimization is needed (e.g., for ocular surface disease), a 3–5 day lead-in treatment period is initiated.
PHASE 2 — SURGICAL PROCEDURE (Day 4–7):
Most corneal transplants are performed under topical anesthesia with intravenous sedation (monitored anesthesia care), or regional retrobulbar block. General anesthesia is reserved for pediatric cases, uncooperative patients, or complex combined procedures.
• DMEK: Duration 45–75 minutes. The descemetorhexis is performed with a reverse Sinskey hook, donor scroll injected via IOL cartridge, unscrolled with targeted BSS jet and air injection. Final 20% SF6 gas fill for overnight tamponade. Patient must maintain supine positioning for 60–90 minutes postoperatively and again the following morning.
• DSAEK: Duration 45–60 minutes. Pre-cut donor lenticule inserted via Busin glide or EndoGlide through 4.5 mm incision. Air bubble tamponade for 60 minutes post-op.
• DALK (Big Bubble): Duration 60–90 minutes. Intrastromal air injection, anterior stromal dissection, donor button secured with 16 interrupted 10-0 nylon sutures.
• PK: Duration 60–90 minutes. Recipient trephination (7.5–8.5 mm), donor button sutured with 16 interrupted or running 10-0 nylon. Subconjunctival dexamethasone and antibiotic injection at conclusion.
PHASE 3 — IMMEDIATE POST-OPERATIVE PERIOD (Days 1–3 post-surgery):
Hospital observation for 1–3 days. For DMEK/DSAEK: IOP monitoring at 1 hour, 6 hours, and next morning to detect pupillary block from air overfill (managed with position change or anterior chamber paracentesis if needed). Visual acuity and graft attachment assessed by slit lamp and AS-OCT. Topical medications initiated: prednisolone acetate 1% q1h (tapering over 12 months), moxifloxacin 0.5% QID, lubricating drops hourly. For DALK/PK: wound integrity assessed; sutures inspected. Patients with DMEK are instructed on the importance of face-up positioning for the first 48–72 hours.
PHASE 4 — EARLY RECOVERY (Weeks 1–3, outpatient):
Follow-up at Day 7: graft attachment confirmed by AS-OCT, IOP rechecked, epithelial healing verified. Visual acuity begins improving at 1–2 weeks for DMEK (often 20/40–20/60 range); PK/DALK patients remain blurry for months pending suture management. No swimming, no eye rubbing, protective shield worn at night. Steroid taper begins. At Week 3, the treating ophthalmologist issues a fitness-to-fly assessment. For uncomplicated lamellar grafts (DMEK, DSAEK), most patients are cleared for international travel at 3 weeks, provided: graft is fully attached on AS-OCT, IOP is stable, no signs of rejection, and adequate topical medication supply is dispensed for the journey.
PHASE 5 — INTERMEDIATE RECOVERY (Months 1–6):
For DMEK/DSAEK: Best-corrected vision typically stabilizes at 3–6 months. Endothelial cell density assessed at 3 and 6 months by specular microscopy. Suture-free recovery means no suture-related astigmatism. For DALK/PK: Selective suture removal begins at 6–12 months guided by topographic astigmatism maps; full visual potential not realized until sutures are partially or fully removed (12–24 months). Rejection surveillance education provided — patients must recognize and respond immediately to symptoms of rejection (RSVP: Redness, Sensitivity to light, decreased Vision, Pain).
PHASE 6 — LONG-TERM FOLLOW-UP (Months 6–24+):
GAF Healthcare coordinates teleconsultation follow-up with the operating surgeon at 6, 12, and 24 months. Endothelial cell density tracking is the primary biomarker of graft health. Local ophthalmologist coordination letters (in English and the patient's language) are provided for continuity of care. Steroid taper continues for minimum 12 months; high-risk patients continue low-dose topical steroids indefinitely. Optical rehabilitation: spectacles or rigid gas-permeable contact lenses for DALK/PK patients; LASIK enhancement over a stable DMEK graft may be considered after 12 months in select cases.
Risks & Considerations
Corneal and ocular tissue transplantation is among the safest and most successful organ transplant procedures performed worldwide, yet patients must be counseled thoroughly about procedure-specific risks. The most clinically significant risk is immunological graft rejection, which manifests as subepithelial infiltrates, keratic precipitates, stromal edema, or Khodadoust line (endothelial rejection line). Rejection does not mean graft failure — if recognized early and treated aggressively with intensive topical corticosteroids (prednisolone acetate 1% q1h) and sometimes systemic methylprednisolone, irreversible failure can often be prevented. The cumulative 5-year rejection rate is approximately 1% per year for DMEK, 3–5% for DSAEK, and 5–8% for PK. Primary graft failure — non-function of the donor endothelium from the outset, typically due to donor tissue quality or surgical trauma — occurs in approximately 1–2% of DMEK cases and less in DSAEK. DMEK-specific complications include graft detachment or partial detachment (requiring rebubbling, an office procedure, in 10–15% of cases when performed by surgeons in early learning curves; 3–5% at expert centers), pupillary block from air overfill (managed by anterior chamber paracentesis), and scroll manipulation difficulty. DALK-specific risks include intraoperative perforation of Descemet's membrane (requiring conversion to PK) in approximately 5–10% of cases depending on surgeon experience. PK-specific risks include wound dehiscence from trauma (lifelong risk), significantly induced astigmatism (mean 3–5 diopters), suture-related complications (loosening, infection, vascularization), and the longest rejection surveillance window. Across all techniques, risks include elevated intraocular pressure or steroid-induced glaucoma (requiring topical or surgical IOP management), infectious keratitis or endophthalmitis (rare, <0.1%), cataract progression (particularly in PK), and chronic ocular surface disease. Limbal stem cell transplantation carries the additional risks of donor site complications (in autograft), allograft rejection requiring systemic immunosuppression, and graft-versus-host-related ocular surface disease in some allogeneic cases. Patients with pre-existing corneal vascularization, prior failed grafts, systemic autoimmune disease, or dry eye represent higher-risk populations requiring individualized counseling, HLA matching strategy, and potentially adjunctive systemic immunosuppression.
Top Hospitals for Eye Transplant (Ocular Tissue)
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
All India Institute of Medical Sciences (AIIMS)
New Delhi, India
Christian Medical College (CMC)
Vellore, India
Manipal Hospitals Dwarka
New Delhi, India
Top Doctors for Eye Transplant (Ocular Tissue)
Internationally trained specialists in Ophthalmology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Abhishek Hoshing
MBBS, MS (Ophthalmology), Fellowship (Advanced Ophthalmic Subspecialties)
Ophthalmologist
Apollo Hospitals, Navi Mumbai, Mumbai, India
9+ Yearsof experience
Dr. Abhishek Hoshing is a Senior Consultant Ophthalmologist at Apollo Hospitals, Navi Mumbai, bringing over nine years of dedicated experience in eye care. He works across a wide spectrum of ophthalmic conditions — from everyday refractive concerns to complex retinal and corneal disorders — and is particularly known for his expertise in cataract surgery, glaucoma management, and the treatment of diabetic eye disease. Dr. Hoshing completed both his MBBS… Read more
Dr. Ajit Babu Majji
MBBS, MD Ophthalmology, FRCS, Vitreo-Retinal Surgery Fellowship
Vitreo-Retinal Surgeon & Ophthalmologist
Yashoda Hospitals, Hi-Tech City, Hyderabad, India
37+ Yearsof experience
Dr. Ajit Babu Majji is one of India's most experienced vitreo-retinal specialists, with over 37 years dedicated to protecting and restoring the sight of patients from across the country and around the world. Based at Yashoda Hospitals in Hyderabad's Hi-Tech City, he leads the Vitreo-Retinal Services unit and brings a rare combination of surgical precision, clinical depth, and genuine warmth to every patient he sees. His particular focus is on complex… Read more
Dr. Akshi Sharma
MBBS, MS (Ophthalmology), DNB (Ophthalmology), Long-Term Fellowship — Vitreo-Retina, Uvea, ROP & Cataract
Ophthalmologist & Vitreo-Retina Specialist
The Sight Avenue Eye Hospital, New Delhi, India
10+ Yearsof experience
Dr. Akshi Sharma is an ophthalmologist based in New Delhi with a focused expertise in diseases of the retina and vitreous. Over more than a decade of clinical practice, she has built a reputation for managing complex conditions like retinal detachment, macular holes, diabetic retinopathy, and age-related macular degeneration — conditions that can be sight-threatening if not caught and treated in time. Her academic journey reflects a commitment to… Read more
Dr. Aniel Malhotra
MBBS, MS (Ophthalmology), DOMS (Diploma in Ophthalmic Medicine and Surgery)
Ophthalmologist
Indraprastha Apollo Hospital, New Delhi, India
35+ Yearsof experience
Dr. Aniel Malhotra is one of Delhi's most experienced eye specialists, bringing over 35 years of dedicated practice in ophthalmology to his patients at Indraprastha Apollo Hospital. He holds an MBBS, an MS in Ophthalmology, and a DOMS — a combination that reflects both the depth and breadth of his formal training. Over the decades, he has built a reputation for handling some of the most complex eye conditions with calm precision and genuine care. His… Read more
Dr. Annam Sridhar
MBBS, MS, MD
Ophthalmologist
Apollo Hospital, Jubilee Hills, Hyderabad, India
28+ Yearsof experience
Dr. Annam Sridhar is a senior ophthalmologist based at Apollo Hospital, Jubilee Hills, Hyderabad, with more than 28 years of hands-on experience in eye care. His core strengths lie in corneal ophthalmology, refractive laser surgery, and cataract management — areas where patients rely on both technical precision and steady, reassuring guidance. Over the decades, he has built a reputation for being thorough, approachable, and genuinely invested in each… Read more
Frequently Asked Questions — Eye Transplant (Ocular Tissue)
The total cost of eye transplant and ocular tissue transplantation depends primarily on the surgical technique, the recipient eye's complexity, and donor tissue type. In India, costs typically range from $1,500 to $6,000 USD all-inclusive. A straightforward DMEK or DSAEK for Fuchs' dystrophy at a top-tier NABH/JCI-accredited center such as L.V. Prasad Eye Institute or Narayana Nethralaya typically costs $1,500–$3,500 USD, while penetrating keratoplasty, limbal stem cell transplantation, or complex repeat-graft cases range from $3,000–$6,000 USD. In the UAE (Dubai or Abu Dhabi), the same procedures at JCI-accredited, DHA-licensed centers such as Moorfields Eye Hospital Dubai or Cleveland Clinic Abu Dhabi range from $4,000–$14,000 USD — approximately 50–70% higher than India, but still substantially below the $15,000–$30,000+ cost of equivalent procedures in the United Kingdom, United States, or Australia. Both destinations include surgery, anesthesia, donor tissue processing and fees, hospital stay, operating theater charges, and standard post-operative medications in the quoted price. GAF Healthcare provides a free, personalized cost estimate based on the patient's specific diagnostic reports before any commitment is made.
The minimum recommended in-country stay before international air travel is 3 weeks for lamellar keratoplasty procedures (DMEK or DSAEK) and 4–6 weeks for full-thickness penetrating keratoplasty (PK), complex limbal stem cell transplantation, or cases requiring re-bubbling or additional intervention. The critical milestones that must be confirmed before the treating ophthalmologist issues fitness-to-fly clearance are: complete graft attachment verified by anterior-segment OCT, stable intraocular pressure (no residual gas bubble causing pressure concerns), absence of early rejection signs on slit-lamp examination, intact epithelium, and the patient's ability to self-administer topical eye drops correctly. Air travel at standard cabin pressure (equivalent to 6,000–8,000 feet altitude) is generally safe once residual intraocular gas (SF6 or air used for DMEK/DSAEK tamponade) has fully resorbed — which typically occurs within 5–10 days for air and 10–21 days for 20% SF6. Flying with significant intraocular gas carries a risk of dangerously elevated intraocular pressure due to gas expansion at altitude, which is why the 3-week minimum is strongly enforced. GAF Healthcare's care coordinators build a patient stay schedule that accounts for both the surgical date and all mandatory follow-up visits, ensuring that the fitness-to-fly assessment is completed before departure is arranged.
Success rates for ocular tissue transplantation are among the highest in all of transplant medicine, though they vary by technique and patient risk profile. For DMEK (Descemet's Membrane Endothelial Keratoplasty) — the current gold standard for Fuchs' dystrophy and pseudophakic bullous keratopathy — graft survival rates exceed 95% at 5 years at high-volume expert centers, with over 70% of patients achieving best-corrected visual acuity of 20/20 or better. For DSAEK (Descemet's Stripping Automated Endothelial Keratoplasty), 5-year graft survival is approximately 90–93%, with most patients reaching 20/25–20/40 vision. For Deep Anterior Lamellar Keratoplasty (DALK) in keratoconus, visual outcomes rival PK with virtually zero endothelial rejection risk, and graft survival is effectively lifelong in uncomplicated cases since the recipient's own endothelium is preserved. For full-thickness Penetrating Keratoplasty (PK) in standard-risk eyes, 5-year survival is 80–85%, falling to 60–70% in high-risk eyes with corneal vascularization or repeat grafts. Limbal Stem Cell Transplantation (using CLET or SLET techniques) achieves epithelial surface restoration in 70–80% of treated eyes at 12–24 months. The partner centers within the GAF Healthcare network perform these procedures at volumes that meet or exceed international benchmarks, with outcome data audited annually in compliance with NABH (India) and DHA/JCI (UAE) quality standards. Patients receive a personalized risk-stratified success estimate based on their specific diagnosis, prior surgical history, and donor-recipient matching before surgery is confirmed.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive end-to-end non-medical support for all international patients traveling to India or the UAE for eye transplant and ocular tissue transplantation.
INDIA LOGISTICS: GAF Healthcare's dedicated visa team assists patients in applying for the Indian e-Medical Visa, which is available to nationals of 156 eligible countries through the Indian government's online portal. The e-Medical Visa allows a stay of up to 60 days (extendable), permits entry at 30 designated airports, and allows up to two companion visas (eMedical-X) for attending family members. Processing typically takes 3–5 business days; GAF Healthcare provides the required hospital invitation letter from the partner institution. Recommended hub hospitals include L.V. Prasad Eye Institute (Hyderabad/Chennai), Narayana Nethralaya (Bangalore), Sankara Nethralaya (Chennai), and Dr. Shroff's Charity Eye Hospital (Delhi) — all NABH-accredited and several with JCI accreditation. Airport-to-hospital transfers are arranged in pre-booked, air-conditioned vehicles with an English-speaking GAF coordinator. Attendant accommodation options range from hospital guest houses (approximately $20–40/night) to nearby serviced apartments ($40–80/night). Language interpreter services are available in Arabic, Russian, Swahili, French, and Pashto on request.
UAE LOGISTICS: Patients from most GCC countries, European nations, USA, Canada, Australia, and many Asian and African nations enjoy visa-free or visa-on-arrival entry to the UAE for 30–90 days depending on nationality. For nationals requiring advance visa processing, GAF Healthcare liaises directly with UAE-based sponsors to facilitate medical visit visas. Recommended partner centers include Moorfields Eye Hospital Dubai (JCI-accredited, DHA-licensed), Cleveland Clinic Abu Dhabi (JCI-accredited), and specialized cornea services at Magrabi Eye Hospital Dubai. Dubai's strategic geographic location ensures flight access from virtually all international origins within 8 hours, making it ideal for patients who prefer minimal travel time. GAF Healthcare coordinates private airport transfers, hotel accommodation near the hospital (typically 4–5 star serviced apartments within 5–10 minutes of the facility, $80–180/night), and bilingual medical coordinators. Translation services are available in Arabic (native), English, Russian, Urdu, and French. A 24/7 emergency contact line is maintained for all active patients throughout their in-country stay.
BOTH DESTINATIONS: GAF Healthcare provides a pre-travel medical file review (free of charge) wherein the patient's existing reports — topography, specular microscopy, slit-lamp photos, prior surgical records — are reviewed by the specialist team before the patient travels, to confirm candidacy and allow provisional surgical planning. A detailed 'Patient Welcome Pack' is sent electronically covering daily logistics, hospital check-in procedures, medication protocols, and emergency escalation pathways. Post-discharge, teleconsultation follow-up is scheduled with the operating surgeon at 1 week, 1 month, 3 months, and 6 months via the GAF Healthcare patient portal.
Patients Also Explore
Other treatments commonly sought by patients considering Eye Transplant (Ocular Tissue).
Rhinoplasty (Nose Job)
Cosmetic Surgery
Liposuction
Cosmetic Surgery
Cochlear Implant
ENT
Hyperthyroidism Treatment
ENT